Stockscreener 앱 받기
12.01
1.44%
0.17
전일 마감가:
$11.84
열려 있는:
$11.93
하루 거래량:
936.28K
Relative Volume:
1.00
시가총액:
$644.10M
수익:
$59,000
순이익/손실:
$-84.74M
주가수익비율:
-2.0628
EPS:
-5.8222
순현금흐름:
$-59.69M
1주 성능:
-10.57%
1개월 성능:
-25.26%
6개월 성능:
-10.04%
1년 성능:
-13.60%
1일 변동 폭
$11.70
$12.35
1주일 범위
$11.58
$13.82
52주 변동 폭
$11.58
$24.27
아발로 테라퓨틱스 Stock (AVTX) Company Profile
명칭
Avalo Therapeutics Inc
전화
410-522-8707
주소
1500 LIBERTY RIDGE DRIVE, WAYNE
Compare AVTX vs VRTX, MRNA, REGN, ARGX, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AVTX
Avalo Therapeutics Inc
|
12.01 | 644.10M | 59,000 | -84.74M | -59.69M | -5.8222 |
VRTX
Vertex Pharmaceuticals Inc
|
508.75 | 128.95B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
236.50 | 94.42B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
796.34 | 81.99B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
846.27 | 53.22B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
374.08 | 42.32B | 5.76B | 514.49M | 1.10B | 4.4813 |
아발로 테라퓨틱스 Stock (AVTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-07-06 | 개시 | Leerink Partners | Outperform |
| 2026-06-12 | 개시 | BofA Securities | Buy |
| 2026-04-09 | 개시 | Wolfe Research | Outperform |
| 2026-04-06 | 개시 | Citizens | Mkt Outperform |
| 2026-02-02 | 개시 | Guggenheim | Buy |
| 2025-12-18 | 개시 | Mizuho | Outperform |
| 2025-09-17 | 재확인 | H.C. Wainwright | Buy |
| 2025-09-05 | 개시 | TD Cowen | Buy |
| 2025-08-15 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-06-02 | 재개 | H.C. Wainwright | Buy |
| 2025-03-25 | 개시 | Jefferies | Buy |
| 2025-03-25 | 개시 | Stifel | Buy |
| 2025-02-28 | 개시 | Piper Sandler | Overweight |
| 2025-02-21 | 개시 | Wedbush | Outperform |
| 2024-12-19 | 개시 | BTIG Research | Buy |
| 2024-10-24 | 개시 | H.C. Wainwright | Neutral |
| 2024-04-16 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2021-09-24 | 개시 | RBC Capital Mkts | Outperform |
모두보기
아발로 테라퓨틱스 주식(AVTX)의 최신 뉴스
In lieu of Board fees, Avalo Therapeutics (AVTX) grants Rita Jain 1,322 fully vested stock options. - Stock Titan
1,352 fully vested options replace Board fees for Avalo Therapeutics (AVTX) director Kevin Robert Lind. - Stock Titan
In lieu of board fees, Avalo Therapeutics (AVTX) grants Ron M. Philip 1,109 stock options. - Stock Titan
Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Three new hires receive options to buy Avalo shares for $15.47 each - Stock Titan
Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Avalo Therapeutics CFO Christopher Sullivan Executes Option Exercise and Sells 12,394 Shares via 10b5-1 Plan - Kalkine Media
Avalo Therapeutics (AVTX) CFO sells 12K shares after option exercise - Stock Titan
AVTX 8-K FilingsAvalo Therapeutics, Inc. SEC 8-K - Stock Titan
Avalo Therapeutics (AVTX) CFO sells shares at $17.62 average, keeps 105K options - Stock Titan
Avalo Therapeutics at Cantor conference: building around il-1 beta By Investing.com - Investing.com Canada
(AVTX) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) - Moomoo
Avalo Therapeutics Inc. (AVTX) Peer Comparison – Compare with Others - Value Research
Avalo Therapeutics Inc. (AVTX) Key Financial Ratios – Valuation, Profitability & More - Value Research
Avalo Therapeutics: Phase 2 Validation Has Created An IL-1β Franchise (NASDAQ:AVTX) - Seeking Alpha
Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Six new hires get options to buy 78,000 Avalo shares - Stock Titan
Avalo Therapeutics Inc. (AVTX) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Avalo Therapeutics to Participate in Upcoming Investor Conferences - Yahoo Finance
Avalo Therapeutics CMO Mittie Doyle sells $20,000 in stock By Investing.com - Investing.com South Africa
Avalo Therapeutics CMO Mittie Doyle sells $20,000 in stock - Investing.com
Avalo Therapeutics CMO Mittie Doyle sells $20,000 in stock By Investing.com - Investing.com Nigeria
Avalo Therapeutics CMO Mittie Doyle sells $20,000 in stock By Investing.com - Investing.com Canada
Avalo Therapeutics CMO Mittie Doyle sells $20,000 in stock By Investing.com - Investing.com India
Avalo Therapeutics CMO Mittie Doyle sells $20,000 in stock By Investing.com - Investing.com UK
Avalo Therapeutics CFO Sullivan sells over $1.4m in stock By Investing.com - Investing.com Canada
Avalo Therapeutics CFO Sullivan sells over $1.4m in stock - Investing.com
Avalo Therapeutics CFO Sullivan sells over $1.4m in stock By Investing.com - Investing.com Australia
Avalo Therapeutics (AVTX) CMO trades shares under 10b5-1 plan - Stock Titan
Avalo Therapeutics Inc. (AVTX) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
How Avalo Therapeutics Inc. (AVTX) Affects Rotational Strategy Timing - Stock Traders Daily
Avalo Therapeutics chief medical officer Mittie Doyle sells $20,000 shares By Investing.com - Investing.com Nigeria
Avalo Therapeutics chief medical officer Mittie Doyle sells $20,000 shares - Investing.com India
Avalo Therapeutics CFO sells over $1.45 million in stock By Investing.com - Investing.com Nigeria
Avalo Therapeutics CFO sells over $1.45 million in stock By Investing.com - Investing.com India
Avalo Therapeutics CFO sells over $1.45 million in stock By Investing.com - Investing.com UK
Avalo Therapeutics chief medical officer Mittie Doyle sells $20,000 shares - investing.com
AVTX | Avalo Therapeutics, Inc. Common FinancialsRevenue Breakdown - quiverquant.com
Avalo Therapeutics, Inc. Revenue Breakdown – NASDAQ:AVTX - TradingView
Deep Track Capital, LP Expands Avalo Therapeutics Inc (AVTX) Sta - GuruFocus
Avalo (AVTX) Q2 2026 Earnings: The EPS Result Is Below Expectation in the Latest Session; Post-Report: Shares Move 5.28% UpRevenue Growth Outlook - vinanet.vn
Avalo Therapeutics CMO Mittie Doyle Executes Stock Option and Sells 1,000 Shares Under 10b5-1 Plan - Kalkine Media
Avalo Therapeutics (AVTX) CMO sells 1,000 shares in plan - Stock Titan
Avalo Therapeutics Insider Sold Shares Worth $1,450,419, According to a Recent SEC Filing - marketscreener.com
Avalo Therapeutics (AVTX) CFO sells 72K shares in 10b5-1 trades - Stock Titan
Avalo (AVTX) Financial Update: Profit Per Share Falls Below Its Benchmark in Latest Trading; Post-Report - vinanet.vn
Avalo Therapeutics CFO Christopher Ryan Sullivan Executes Stock Options and Sells Shares Over Two Days - Kalkine Media
Avalo Therapeutics (NASDAQ: AVTX) insider lines up new stock sale after $74K August trade - Stock Titan
Avalo Therapeutics (AVTX) insider lines up $98.7K stock sale - Stock Titan
아발로 테라퓨틱스 (AVTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
아발로 테라퓨틱스 주식 (AVTX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Sullivan Christopher Ryan | Chief Financial Officer |
Sep 16 '26 |
Sale |
16.33 |
12,394 |
202,437 |
39,900 |
| Sullivan Christopher Ryan | Chief Financial Officer |
Sep 10 '26 |
Option Exercise |
8.04 |
10,185 |
81,887 |
50,085 |
| Sullivan Christopher Ryan | Chief Financial Officer |
Sep 10 '26 |
Sale |
17.62 |
10,185 |
179,457 |
39,900 |
| Doyle Mittie | Chief Medical Officer |
Aug 28 '26 |
Sale |
20.00 |
679 |
13,580 |
51,776 |
| Doyle Mittie | Chief Medical Officer |
Aug 28 '26 |
Option Exercise |
8.04 |
679 |
5,459 |
52,455 |
| Sullivan Christopher Ryan | Chief Financial Officer |
Aug 18 '26 |
Option Exercise |
9.88 |
31,031 |
306,586 |
70,931 |
| Sullivan Christopher Ryan | Chief Financial Officer |
Aug 18 '26 |
Sale |
20.05 |
31,031 |
622,324 |
39,900 |
| CHRISTOPHER RYAN SULLIVAN | Officer |
Aug 18 '26 |
Proposed Sale |
20.05 |
31,031 |
622,221 |
0 |
| CHRISTOPHER RYAN SULLIVAN | Officer |
Aug 17 '26 |
Proposed Sale |
19.59 |
70,709 |
1,385,189 |
0 |
| Sullivan Christopher Ryan | Chief Financial Officer |
Aug 17 '26 |
Option Exercise |
9.88 |
40,821 |
403,311 |
81,594 |
15.34%
자본화:
|
볼륨(24시간):